Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 3 of 8812345...102030...Last »

Rhythm Pharmaceuticals Publishes Longer-Term Data on LEPR Deficiency Obesity Study

As Boston-based Rhythm Pharmaceuticals moves its lead obesity treatment into a second Phase III trial, the company was bolstered by the publication of longer-term data from its Phase II study of setmelanotide in Nature Medicine.

Read More »

Roche’s Tecentriq fails key cancer trial

Roche’s hopes of Tecentriq catching rival medicines from Merck and Bristol-Myers Squibb were dealt a blow after the immunotherapy failed a key combination trial.

Read More »

Janssen Closes in on Seeking FDA Approval for Ketamine-Based Depression Treatment

Janssen Pharmaceuticals is eying a potential breakthrough in treating refractory major depressive disorder.

Read More »

Celgene Plans To File 2nd NDA for Ozanimod in 2019

Celgene is eying the first quarter of 2019 to submit a second New Drug Application (NDA) for the multiple sclerosis treatment ozanimod.

Read More »

Scientists devise more accurate peanut allergy test

British scientists have developed a far more accurate blood test to diagnose peanut allergy, offering a better way to monitor a significant food hazard.

Read More »

More sauna visits tied to lower risk of stroke

A Finnish study suggests a regular sauna habit is associated with a lower risk of strokes.

Read More »

Bristol-Myers Squibb Abandons Two Phase III Trials of IDO1 Inhibitor Program

Bristol-Myers dropped two Phase III clinical trials of the IDO1 inhibitor acquired from Flexus Biosciences.

Read More »

Migraine drug succeeds in second late-stage trial

Allergan Plc announced positive results from a second Phase III trial for a 50-milligram dose of the company’s drug for acute migraine, reproducing results from the previous clinical study.

Read More »

Study: 44 genetic risk factors for major depression

International scientists identified 44 genetic variants that can increase the risk of developing major depression and found that all humans carry at least some of them.

Read More »

Boehringer Ingelheim R&D Pushes to Transcend Disease Boundaries

Boehringer Ingelheim presented the family-owned pharmaceutical company’s latest pipeline updates at an R&D press conference entitled ‘Transcending Disease Boundaries’ at its global headquarters in Ingelheim, Germany.

Read More »

Cancer immunotherapy combo flops in study

The concept of combining two immunotherapy drugs to fight lung cancer suffered a fresh blow from the failure of an AstraZeneca clinical study.

Read More »

FDA panel against higher dose of arthritis drug

An arthritis drug developed by Eli Lilly and Co. and Incyte Corp. should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted.

Read More »

Bluebird Bio One Step Closer to First Approved Drug

Bluebird bio announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia (TDT).

Read More »

Gates backs gene technologies in fight to end malaria

Gene-editing technologies that alter mosquitoes’ DNA could prove critical in the fight against malaria, Bill Gates said, and ethical concerns should not block progress in such gene-modifying research.

Read More »

Eli Lilly Shows Off More Verzenio Data at AACR

Eli Lilly unveiled final data from the MONARCH 3 study that helped the drug garner FDA approval in February 2018 for the treatment of some breast cancer patients.

Read More »

Janssen, Bristol-Myers Squibb to Develop Therapy

Janssen Pharmaceuticals has teamed up with Bristol-Myers Squibb to drive BMS-986177, a Factor XIa (FXIa) inhibitor, into Phase II development for the study of secondary stroke prevention and major thrombotic conditions.

Read More »

Amgen’s Aimovig halved migraine days in 30 percent of trial patients

A late-stage trial of Amgen Inc.’s Aimovig found that the experimental drug reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments.

Read More »

Survival data boosts Keytruda lead in lung cancer

Merck & Co.’s immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly diagnosed patients with advanced non-small cell lung cancer in a highly anticipated study.

Read More »

CRISPR Therapeutics Plans to Treat First Patients for Beta Thalassemia in Europe

CRISPR Therapeutics is ready to begin treating patients in Europe using the company’s CRISPR gene-editing tool. The plan is to treat patients with beta thalassemia, a blood disorder that decreases the production of hemoglobin, the iron-containing protein in red blood cells that carries oxygen.

Read More »

Trial Failure for Pfizer’s Inlyta for Kidney Cancer

An Independent Monitoring Committee recommended that Pfizer halt the Phase III ATLAS trial of Inlyta (axitinib) because it was not proving effective.

Read More »

Page 3 of 8812345...102030...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2018 Focus: Agency Profiles, Manny Awards and Annual Review

Subscribe

Ad Right Bottom

Main Navigation